Calquence Approved for Mantle Cell Lymphoma
TUESDAY, Oct. 31, 2017 -- Calquence (acalabrutinib) has been approved by the U.S. Food and Drug Administration to treat adults with mantle cell lymphoma.
Mantle cell is an aggressive, fast-growing non-Hodgkin lymphoma, a cancer of the lymph system....
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | General Medicine | Lymphoma | Non-Hodgkin's Lymphoma